藥明康德(603259.SH)業績快報：半年度淨利潤升62.49%至17.17億元
格隆匯 7 月 20日丨藥明康德(603259.SH)披露2020年半年度業績快報，實現營業總收入72.31億元，同比增長22.68%；營業利潤19.31億元，同比增長50.05%；歸屬於上市公司股東的淨利潤17.17億元，同比增長62.49%；歸屬於上市公司股東的扣除非經常性損益的淨利潤11.31億元，同比增長13.91%；基本每股收益0.75元。
其中，第二季度，實現營業總收入40.44億元，同比增長29.41%；營業利潤15.11億元，同比增長93.91%；歸屬於上市公司股東的淨利潤14.14億元，同比增長111.46%；歸屬於上市公司股東的扣除非經常性損益的淨利潤7.55億元，同比增長51.67%。
在公司美國區實驗室服務的收入和利潤因為2020年第二季度美國新冠疫情加重受到較大負面影響的情況下，公司中國區實驗室和合同研發與生產業務(CDMO)在第二季度全面恢復正常運營。同時，隨着海外客户訂單的較快增長，以及公司產能利用和經營效率的不斷提升，使公司第二季度營業收入實現強勁增長。公司臨牀試驗服務(CRO)和現場管理服務(SMO)業務自二季度起也處於逐步恢復中。
非經常性損益項目影響方面，公司2020年上半年度非經常性損益項目的影響與上年同期相比有所增長，主要由於公司所投資的已上市公司標的市場價值上漲等原因，使公司部分非流動金融資產的公允價值變動收益以及投資收益增長較大，合計影響金額預計約人民幣10.31億元左右，相比上年同期為淨損失人民幣1824.59萬元。其中，公司變更對一被投資聯營公司股份的會計核算方式引起的投資收益增長約人民幣3.51億元，公司已於2020年6月11日公告上述事項。同時，公司可轉債的衍生金融工具部分的公允價值受公司股價大幅上漲影響，未實現公允價值損失金額預計約人民幣4.87億元左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
